<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153022">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01889290</url>
  </required_header>
  <id_info>
    <org_study_id>RELZH12</org_study_id>
    <nct_id>NCT01889290</nct_id>
  </id_info>
  <brief_title>Methylnaltrexone Pharmacokinetics in Neurointensive Care Patients</brief_title>
  <acronym>RELZH12</acronym>
  <official_title>Pharmacokinetics of Once Daily Subcutaneous Methylnaltrexone in Neurointensive Care Patients With High Dose Sufentanil Analgosedation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Assessment of pharmacokinetic parameters of once daily subcutaneously administered
           methylnaltrexone in 10 evaluable neurointensive care patients.

        -  Quantification of methylnaltrexone passage through the blood-brain-barrier in
           critically ill patients with severe cerebral affections.

        -  Observation of laxation response after methylnaltrexone application and relation to
           plasma concentrations of methylnaltrexone.

        -  Assessing the safety of once daily administered methylnaltrexone in neurointensive care
           patients.

        -  Trial with medicinal product
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After administration of methylnaltrexone s.c. multiple peripheral blood samples  and
      additionally two liquor samples are drawn during a dose interval on day 1, 3, and 5 of drug
      administration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of methylnaltrexone (Cmax, tmax, area under the curve, total clearance, halflife, accumulation ratio, renal clearance)</measure>
    <time_frame>5 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Opioid Use, Unspecified With Other Opioid-induced Disorder</condition>
  <arm_group>
    <arm_group_label>Methylnaltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmacokinetics of methylnaltrexone administered once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylnaltrexone</intervention_name>
    <description>Methylnaltrexone 12mg s.c. administered once daily until treatment stop of sufentanyl</description>
    <arm_group_label>Methylnaltrexone</arm_group_label>
    <other_name>Relistor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  hospitalisation in the neurointensive care unit

          -  deep sedation with sufentanil doses of = 40 mcg/h

          -  male or female aged 18 years or older

          -  females: negative pregnancy test

          -  Ventricular drainage as part of needed therapeutic measures

        Exclusion criteria:

          -  History of hypersensitivity to methylnaltrexone (RelistorÂ®)

          -  confirmed or suspected obstructive ileus or factors possibly leading to intestinal
             obstruction (e.g. an intestinal tumor)

          -  increased risk for patients with localized or diffused reduction in structural
             integrity of the gastrointestinal tract (e.g. peptic ulcer, acute diverticulitis)

          -  severe hepatic insufficiency (Child-Pugh Class C)

          -  renal impairment (glomerular filtration rate &lt; 90 ml/min) with or without renal
             replacement therapy

          -  severe diarrhea despite high opioid dosing

          -  participation in another study with an investigational drug within the 30 days
             preceding and during the present study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natascia Corti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Pharmacology and Toxicology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corti Natascia, MD</last_name>
    <email>natascia.corti@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neurointensive Care Unit</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 27, 2014</lastchanged_date>
  <firstreceived_date>June 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>methylnaltrexone</keyword>
  <keyword>opioid-antagonist</keyword>
  <keyword>Obstipation</keyword>
  <keyword>pharmacokinetics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylnaltrexone</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
